28 Nov 2024 · 1 min read
The AI-driven techbio revolution is heating up:
Cradle, a Netherlands-based generative AI biotech startup, just raised a $73M Series B — a round that's truly big by EU standards and signals the explosive growth of AI-driven drug discovery. I see real parallels to the rise of Veeva, and the coming years promise to be game-changing.